Ensysce Biosciences Inc Financials
This page shows Ensysce Biosciences Inc (ENSC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Ensysce Biosciences Inc has an operating margin of -202.1%, meaning the company retains $-202 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -129.2% the prior year.
Ensysce Biosciences Inc's revenue declined 2.8% year-over-year, from $5.2M to $5.1M. This contraction results in a growth score of 29/100.
Ensysce Biosciences Inc carries a low D/E ratio of 1.42, meaning only $1.42 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 73/100, indicating a strong balance sheet with room for future borrowing.
Ensysce Biosciences Inc's current ratio of 1.59 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 27/100, which could limit financial flexibility.
While Ensysce Biosciences Inc generated -$7.8M in operating cash flow, capex of $124K consumed most of it, leaving -$7.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Ensysce Biosciences Inc generates a -316.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -215.4% the prior year.
Ensysce Biosciences Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Ensysce Biosciences Inc generates $0.77 in operating cash flow (-$7.8M OCF vs -$10.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Ensysce Biosciences Inc earns $-826.3 in operating income for every $1 of interest expense (-$10.2M vs $12K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Ensysce Biosciences Inc generated $5.1M in revenue in fiscal year 2025. This represents a decrease of 2.8% from the prior year.
Ensysce Biosciences Inc's EBITDA was -$10.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 52.1% from the prior year.
Ensysce Biosciences Inc reported -$10.2M in net income in fiscal year 2025. This represents a decrease of 27.4% from the prior year.
Ensysce Biosciences Inc earned $-3.98 per diluted share (EPS) in fiscal year 2025. This represents an increase of 65.2% from the prior year.
Cash & Balance Sheet
Ensysce Biosciences Inc generated -$7.9M in free cash flow in fiscal year 2025, representing cash available after capex.
Ensysce Biosciences Inc held $4.3M in cash against $0 in long-term debt as of fiscal year 2025.
Ensysce Biosciences Inc had 9M shares outstanding in fiscal year 2025. This represents an increase of 584.3% from the prior year.
Margins & Returns
Ensysce Biosciences Inc's operating margin was -202.1% in fiscal year 2025, reflecting core business profitability. This is down 72.9 percentage points from the prior year.
Ensysce Biosciences Inc's net profit margin was -200.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 47.6 percentage points from the prior year.
Ensysce Biosciences Inc's ROE was -316.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 101.3 percentage points from the prior year.
Capital Allocation
Ensysce Biosciences Inc invested $10.4M in research and development in fiscal year 2025. This represents an increase of 43.7% from the prior year.
Ensysce Biosciences Inc invested $124K in capex in fiscal year 2025, funding long-term assets and infrastructure.
ENSC Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $493K-64.0% | $1.4M+3.9% | $1.3M+1.2% | $1.3M-61.9% | $3.4M+1780.6% | $182K-40.5% | $306K-40.6% | $515K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $3.0M+53.6% | $1.9M+2.0% | $1.9M-50.4% | $3.8M+124.9% | $1.7M+78.5% | $947K+21.6% | $779K-65.1% | $2.2M |
| SG&A Expenses | $1.3M+6.7% | $1.2M-14.5% | $1.4M+30.1% | $1.1M-0.5% | $1.1M-9.0% | $1.2M-13.1% | $1.4M-4.7% | $1.4M |
| Operating Income | -$3.7M-113.7% | -$1.8M+11.0% | -$2.0M+45.0% | -$3.6M-654.7% | $645K+133.0% | -$2.0M-6.1% | -$1.8M+41.6% | -$3.2M |
| Interest Expense | $3K | $0-100.0% | $909+100.1% | -$1.2M-30703.7% | $4K+2645.3% | $148-100.0% | $1.2M+262.0% | $345K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.7M-115.1% | -$1.7M+10.9% | -$1.9M+45.4% | -$3.6M-638.6% | $662K+133.6% | -$2.0M+36.9% | -$3.1M+11.1% | -$3.5M |
| EPS (Diluted) | $-1.29-63.3% | $-0.79+43.2% | $-1.39 | N/A | $1.00+129.9% | $-3.35+59.2% | $-8.21 | N/A |
ENSC Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.2M-43.0% | $5.6M+20.9% | $4.6M-17.6% | $5.6M-40.4% | $9.4M+235.7% | $2.8M-44.9% | $5.1M+87.4% | $2.7M |
| Current Assets | $2.9M-44.6% | $5.3M+20.0% | $4.4M-17.7% | $5.3M-41.2% | $9.1M+269.6% | $2.5M-47.6% | $4.7M+105.2% | $2.3M |
| Cash & Equivalents | $1.7M-24.3% | $2.2M-27.5% | $3.1M-12.8% | $3.5M-15.7% | $4.2M+298.1% | $1.0M-69.4% | $3.4M+203.0% | $1.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.3M-8.3% | $2.5M+32.9% | $1.9M-14.7% | $2.2M-21.0% | $2.8M+113.1% | $1.3M-20.4% | $1.7M-50.8% | $3.4M |
| Current Liabilities | $2.3M-8.3% | $2.5M+42.7% | $1.8M-20.2% | $2.2M-21.2% | $2.8M+114.4% | $1.3M-20.1% | $1.6M-50.9% | $3.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.2M-64.5% | $3.4M+11.2% | $3.0M-17.8% | $3.7M-46.3% | $6.9M+282.1% | $1.8M-51.8% | $3.7M+1261.2% | -$323K |
| Retained Earnings | -$137.0M-2.8% | -$133.2M-1.3% | -$131.5M-1.5% | -$129.5M-2.8% | -$126.0M+0.5% | -$126.6M-1.6% | -$124.7M-2.6% | -$121.6M |
ENSC Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.9M+31.1% | -$2.7M-58.5% | -$1.7M-123.5% | -$764K+25.1% | -$1.0M+55.8% | -$2.3M+32.2% | -$3.4M-89.2% | -$1.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $1.5M-22.2% | $1.9M+48.3% | $1.3M+1017.3% | $113K-97.3% | $4.1M+8163.5% | -$51K-100.9% | $5.7M+289.4% | $1.5M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ENSC Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -758.7%-631.0pp | -127.6%+21.4pp | -149.1%+125.3pp | -274.3%-293.2pp | 18.9%+1094.5pp | -1075.6%-472.8pp | -602.8%+9.9pp | -612.7% |
| Net Margin | -756.3%-629.9pp | -126.4%+21.0pp | -147.4%+126.0pp | -273.4%-292.8pp | 19.4%+1101.8pp | -1082.4%-63.0pp | -1019.4%-339.0pp | -680.4% |
| Return on Equity | -309.9%-258.7pp | -51.1%+12.7pp | -63.8%+32.3pp | -96.1%-105.7pp | 9.6%+118.4pp | -108.9%-25.7pp | -83.1% | N/A |
| Return on Assets | -117.3%-86.2pp | -31.1%+11.1pp | -42.2%+21.5pp | -63.7%-70.7pp | 7.0%+77.4pp | -70.4%-9.0pp | -61.4%+68.0pp | -129.4% |
| Current Ratio | 1.27-0.8 | 2.10-0.4 | 2.50+0.1 | 2.42-0.8 | 3.24+1.4 | 1.88-1.0 | 2.87+2.2 | 0.69 |
| Debt-to-Equity | 1.92+1.2 | 0.74+0.1 | 0.62+0.0 | 0.60+0.2 | 0.41-0.3 | 0.73+0.3 | 0.44+10.8 | -10.40 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Ensysce Biosciences Inc's annual revenue?
Ensysce Biosciences Inc (ENSC) reported $5.1M in total revenue for fiscal year 2025. This represents a -2.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ensysce Biosciences Inc's revenue growing?
Ensysce Biosciences Inc (ENSC) revenue declined by 2.8% year-over-year, from $5.2M to $5.1M in fiscal year 2025.
Is Ensysce Biosciences Inc profitable?
No, Ensysce Biosciences Inc (ENSC) reported a net income of -$10.2M in fiscal year 2025, with a net profit margin of -200.9%.
What is Ensysce Biosciences Inc's EBITDA?
Ensysce Biosciences Inc (ENSC) had EBITDA of -$10.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ensysce Biosciences Inc's operating margin?
Ensysce Biosciences Inc (ENSC) had an operating margin of -202.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Ensysce Biosciences Inc's net profit margin?
Ensysce Biosciences Inc (ENSC) had a net profit margin of -200.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Ensysce Biosciences Inc's return on equity (ROE)?
Ensysce Biosciences Inc (ENSC) has a return on equity of -316.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Ensysce Biosciences Inc's free cash flow?
Ensysce Biosciences Inc (ENSC) generated -$7.9M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ensysce Biosciences Inc's operating cash flow?
Ensysce Biosciences Inc (ENSC) generated -$7.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Ensysce Biosciences Inc's total assets?
Ensysce Biosciences Inc (ENSC) had $7.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Ensysce Biosciences Inc's capital expenditures?
Ensysce Biosciences Inc (ENSC) invested $124K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Ensysce Biosciences Inc spend on research and development?
Ensysce Biosciences Inc (ENSC) invested $10.4M in research and development during fiscal year 2025.
What is Ensysce Biosciences Inc's current ratio?
Ensysce Biosciences Inc (ENSC) had a current ratio of 1.59 as of fiscal year 2025, which is generally considered healthy.
What is Ensysce Biosciences Inc's debt-to-equity ratio?
Ensysce Biosciences Inc (ENSC) had a debt-to-equity ratio of 1.42 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ensysce Biosciences Inc's return on assets (ROA)?
Ensysce Biosciences Inc (ENSC) had a return on assets of -136.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Ensysce Biosciences Inc's cash runway?
Based on fiscal year 2025 data, Ensysce Biosciences Inc (ENSC) had $4.3M in cash against an annual operating cash burn of $7.8M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Ensysce Biosciences Inc's Piotroski F-Score?
Ensysce Biosciences Inc (ENSC) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ensysce Biosciences Inc's earnings high quality?
Ensysce Biosciences Inc (ENSC) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Ensysce Biosciences Inc cover its interest payments?
Ensysce Biosciences Inc (ENSC) has an interest coverage ratio of -826.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Ensysce Biosciences Inc?
Ensysce Biosciences Inc (ENSC) scores 22 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.